title: Peptidergic nociceptors of both trigeminal and dorsal root ganglia express serotonin 1D receptors: implications for the selective antimigraine action of triptans.
abstract: Agonists at serotonin 1D (5-HT1D) receptors relieve migraine headache but are not clinically used as general analgesics. One possible explanation for this difference is that 5-HT1D receptors are preferentially expressed by cranial afferents of the trigeminal system. We compared the distribution of 5-HT1D receptor-immunoreactive (5-HT1D-IR) peripheral afferents within the trigeminal ganglion (TRG) and lumbar dorsal root ganglion (DRG) of the rat. We also examined the neurochemical identity of 5-HT1D-IR neurons with markers of primary afferent nociceptors, peripherin, isolectin B4, and substance P, and markers of myelinated afferents, N52 and SSEA3. We observed a striking similarity in the size, distribution, and neurochemical identity of 5-HT1D-IR neurons in TRG and lumbar DRG afferents. Furthermore, the vast majority of 5-HT1D-IR neurons are unmyelinated peptidergic afferents that distribute peripherally, including the dura, cornea, and the sciatic nerve. In the central projections of these afferents within the trigeminal nucleus caudalis and the spinal cord dorsal horn, 5-HT1D-IR fibers are concentrated in laminas I and outer II; a few axons penetrate to lamina V. At the ultrastructural level, 5-HT1D receptors in the spinal cord dorsal horn are localized exclusively within dense core vesicles of synaptic terminals. We observed scattered 5-HT1D-IR neurons in the nodose ganglia, and there was sparse terminal immunoreactivity in the solitary nucleus. The visceral efferents of the superior cervical ganglia did not contain 5-HT1D immunoreactivity. Our finding, that 5-HT1D receptors are distributed in nociceptors throughout the body, raises the possibility that triptans can regulate not only headache-associated pain but also nociceptive responses in extracranial tissues.
authors.affiliation: Department of Neurology, University of California, San Francisco, San Francisco, California 94143-0452, USA.
authors.forename: Sonja
authors.initials: S
authors.lastname: Potrebic
authors.forename: Andrew H
authors.initials: AH
authors.lastname: Ahn
authors.forename: Kate
authors.initials: K
authors.lastname: Skinner
authors.forename: Howard L
authors.initials: HL
authors.lastname: Fields
authors.forename: Allan I
authors.initials: AI
authors.lastname: Basbaum
mesh_terms: D000818:Animals; D000918:Antibody Specificity; D015415:Biomarkers / Q000032:analysis; D017124:Conserved Sequence; D005727:Ganglia, Spinal / Q000166:cytology / Q000378:metabolism*; D008881:Migraine Disorders / Q000188:drug therapy*; D009474:Neurons / Q000145:classification / Q000166:cytology / Q000378:metabolism; D009475:Neurons, Afferent / Q000166:cytology / Q000378:metabolism; D009619:Nociceptors / Q000378:metabolism*; D020671:Posterior Horn Cells / Q000166:cytology / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D044346:Receptor, Serotonin, 5-HT1D / Q000096:biosynthesis* / Q000235:genetics; D058825:Serotonin 5-HT1 Receptor Agonists; D017366:Serotonin Receptor Agonists / Q000494:pharmacology*; D012668:Trigeminal Ganglion / Q000166:cytology / Q000378:metabolism*
chemical_list: D015415:Biomarkers; D044346:Receptor, Serotonin, 5-HT1D; D058825:Serotonin 5-HT1 Receptor Agonists; D017366:Serotonin Receptor Agonists